Collegium Pharmaceutical Inc. News Releases https://ir.collegiumpharma.com/ Collegium Pharmaceutical Inc. News Releases en Collegium to Present at Upcoming Investor Conferences https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-present-upcoming-investor-conferences-8 STOUGHTON, Mass. , May 29, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in June: The Wed, 29 May 2019 08:00:00 -0400 Collegium Pharmaceutical Inc. News Releases 9146 Collegium Reports First Quarter 2019 Financial Results https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-first-quarter-2019-financial-results Xtampza ® ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quarter Basis Net loss of $9.7 million in the First Quarter of 2019 compared to a net loss of $18.7 million in the First Quarter of 2018 Wed, 08 May 2019 16:01:00 -0400 Collegium Pharmaceutical Inc. News Releases 9116 Collegium to Participate in Upcoming Investor Conferences https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-participate-upcoming-investor-conferences STOUGHTON, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences in May: The Tue, 30 Apr 2019 16:01:00 -0400 Collegium Pharmaceutical Inc. News Releases 9106 Collegium to Host Conference Call to Discuss First Quarter 2019 Financial Results and Provide Corporate Update https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-host-conference-call-discuss-first-quarter-2019 STOUGHTON, Mass. , April 24, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a Wed, 24 Apr 2019 16:01:00 -0400 Collegium Pharmaceutical Inc. News Releases 9061 Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-appoints-richard-malamut-md-chief-medical-officer STOUGHTON, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut , M.D., as the company’s first Chief Medical Tue, 02 Apr 2019 08:00:00 -0400 Collegium Pharmaceutical Inc. News Releases 9036 Collegium to Present at Upcoming Investor Conferences https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-present-upcoming-investor-conferences-7 STOUGHTON, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in April: The H.C. Mon, 01 Apr 2019 08:00:00 -0400 Collegium Pharmaceutical Inc. News Releases 9031 Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-fourth-quarter-and-full-year-2018-financial Xtampza ® ER Prescriptions Grew 233% in 2018 Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full Year Cash and Cash Equivalents were $146.6 million as of December 31, 2018 , exceeding year-end cash guidance of $145.0 million Conference call scheduled for Wed, 27 Feb 2019 16:01:00 -0500 Collegium Pharmaceutical Inc. News Releases 8986 Collegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-host-conference-call-discuss-fourth-quarter-2018 STOUGHTON, Mass. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, February 27, 2019 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and Wed, 13 Feb 2019 08:40:00 -0500 Collegium Pharmaceutical Inc. News Releases 8961 Collegium Provides Full-Year 2019 Financial Guidance https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-provides-full-year-2019-financial-guidance – Xtampza ER Revenue Expected in the Range of $95 Million to $105 Million – Nucynta Franchise Revenue Expected in the Range of $200 Million to $210 Million – Total Operating Expenses Expected in the Range of $125 Million to $135 Million STOUGHTON, Mass. , Jan. Mon, 07 Jan 2019 08:00:00 -0500 Collegium Pharmaceutical Inc. News Releases 8861 Collegium to Present at Upcoming Investor Conferences https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-present-upcoming-investor-conferences-6 STOUGHTON, Mass. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from Mon, 12 Nov 2018 07:24:06 -0500 Collegium Pharmaceutical Inc. News Releases 8766